Comparison of BRCA2 Single Nucleotide Variants Between Japanese Patients With Familial Prostate Cancer, Sporadic Prostate Cancer, and Benign Prostatic Hyperplasia.

BACKGROUND/AIM: A family history of prostate cancer is an established risk factor for its development. The BRCA2 gene frequently harbors pathogenic mutations in patients with prostate cancer. This study compared single nucleotide variants (SNVs) in BRCA2 among patients with familial prostate cancer, primarily treated at our institution.

PATIENTS AND

METHODS

SNVs in the BRCA2 gene were analyzed in 141 patients with benign prostatic hyperplasia (BPH), 202 patients with sporadic prostate cancer (SPC), and 151 patients with familial prostate cancer (FPC). We aimed to identify SNVs that were significantly more prevalent in FPC.

RESULTS

The analysis revealed that the G8187T variant was significantly more prevalent in the FPC group than in the BPH and SPC groups. Compared with the BPH group, the odds ratio was 4.93 (95% confidence interval=1.07-22.70, p=0.024). Among 75 cases with available prognostic information, the G8187T (+) variant was identified in six cases, whereas the G8187T (-) variant was found in 69 cases. Kaplan-Meier analysis showed no significant differences in overall (OS) or cancer-specific (CSS) survival between the two groups (OS, p=0.5734; CSS, p=0.2241).

CONCLUSION

The G8187T variant in BRCA2 was significantly associated with familial prostate cancer in Japanese patients, suggesting that it constitutes a risk factor for disease development.